Cogent Biosciences Inc Cash Flow-to-Debt Ratio
Cogent Biosciences Inc cash flow-to-debt ratio. Cogent Biosciences Inc (COGT) has a Cash Flow-to-Debt Ratio of -0.26x as of December 2025, meaning its operating cash flow of $-79.11 Million could theoretically repay 0% of its total liabilities ($301.24 Million) in one year. Check Cogent Biosciences Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cogent Biosciences Inc (2015–2025)
Cash flow-to-debt ratio of Cogent Biosciences Inc from 2015 to 2025. Historical debt coverage capacity for Cogent Biosciences Inc across 11 annual periods. Check COGT cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Cogent Biosciences Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Cogent Biosciences Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Cogent Biosciences Inc. For the full cash flow conversion analysis, see Cogent Biosciences Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.88x | $-264.44 Million | $301.24 Million | ▲ +69.7% |
| 2024 | -2.90x | $-207.79 Million | $71.61 Million | ▼ -5.1% |
| 2023 | -2.76x | $-153.62 Million | $55.63 Million | ▼ -4.9% |
| 2022 | -2.63x | $-118.64 Million | $45.08 Million | ▲ +19.8% |
| 2021 | -3.28x | $-58.76 Million | $17.91 Million | ▼ -48.7% |
| 2020 | -2.21x | $-35.85 Million | $16.25 Million | ▲ +6.1% |
| 2019 | -2.35x | $-41.51 Million | $17.66 Million | ▼ -85.9% |
| 2018 | -1.26x | $-32.49 Million | $25.69 Million | ▼ -1.9% |
| 2017 | -1.24x | $-25.84 Million | $20.81 Million | ▼ -54.3% |
| 2016 | -0.80x | $-18.64 Million | $23.16 Million | ▼ -214.7% |
| 2015 | 0.70x | $17.72 Million | $25.25 Million | — |